Prognostic value of discs large homolog 7 transcript levels in prostate cancer

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Gomez, Christian R ^a,b,c   Kosari, Farhad ^b   Munz, Jan Marie ^b   Schreiber, Claire A ^a   Knutson, Gaylord J ^a   Ida, Cristiane M ^b   El Khattouti, Abdelouahid ^c   Jeffrey Karnes, R ^b   Cheville, John C ^b   Vasmatzis, George ^b   Vuk Pavlović, Stanimir ^a,b  

^a MAYO CLINIC CANCER CENTER   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN B1; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CASE CONTROL STUDY; CONTROLLED STUDY; CYCLIN B1 GENE; DISCS LARGE HOMOLOG 7 GENE; GENE; GENETIC TRANSCRIPTION; GLEASON SCORE; HUMAN; HUMAN TISSUE; HYALURONAN MEDIATED MOTILITY RECEPTOR GENE; HYPOXIA; MAJOR CLINICAL STUDY; MALE; OXYGEN TENSION; PROSTATE CANCER; RECEIVER OPERATING CHARACTERISTIC;

ANOXIA; CASE-CONTROL STUDIES; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; NEOPLASM GRADING; NEOPLASM PROTEINS; NEOPLASM STAGING; PROGNOSIS; PROSTATIC NEOPLASMS; ROC CURVE; TRANSCRIPTION, GENETIC;

EID: 84891913770     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0082833     Document Type: Article

References (50)

1. Warburg O (1956) On the origin of cancer cells. Science 123:309-314. doi:10.1126/science.123.3191.309. PubMed: 13298683.
2. Vaupel P, Kelleher DK, Höckel M (2001) Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy. Semin Oncol 28:29-35. doi:10.1053/sonc.2001.27628. PubMed: 11395850. (Pubitemid 32522235)
3. Chan DA, Giaccia AJ (2007) Hypoxia, gene expression, and metastasis. Cancer Metastasis Rev 26:333-339. doi:10.1007/s10555-007-9063-1. PubMed: 17458506. (Pubitemid 47101666)
4. Stewart GD, Ross JA, McLaren DB, Parker CC, Habib FK et al. (2010) The relevance of a hypoxic tumour microenvironment in prostate cancer. BJU Int 105:8-13. doi:10.1111/j.1464-410X.2009.09151.x. PubMed: 19889065.
5. Movsas B, Chapman JD, Greenberg RE, Hanlon AL, Horwitz EM et al. (2000) Increasing levels of hypoxia in prostate carcinoma correlate significantly with increasing clinical stage and patient age: an Eppendorf pO (2) study. Cancer 89:2018-2024. doi: 10.1002/1097-0142 (20001101) 89:9. PubMed: 11064360.
6. Humphrey PA (2004) Gleason grading and prognostic factors in carcinoma of the prostate. Mod Pathol 17:292-306. doi:10.1038/modpathol.3800054. PubMed: 14976540. (Pubitemid 41646608)
7. Blute ML, Bergstralh EJ, Iocca A, Scherer B, Zincke H (2001) Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. J Urol 165:119-125. doi:10.1097/00005392-200101000-00030. PubMed: 11125379.
8. Bostwick DG, Grignon DJ, Hammond ME, Amin MB, Cohen M, et al. (2000) Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999 Arch Pathol Lab Med 124:995-1000 (Pubitemid 30602040)
9. Kosari F, Munz JM, Savci-Heijink CD, Spiro C, Klee EW et al. (2008) Identification of prognostic biomarkers for prostate cancer. Clin Cancer Res 14:1734-1743. doi:10.1158/1078-0432. CCR-07-1494. PubMed: 18347174. (Pubitemid 351469458)
10. Kube DM, Savci-Heijink CD, Lamblin AF, Kosari F, Vasmatzis G et al. (2007) Optimization of laser capture microdissection and RNA amplification for gene expression profiling of prostate cancer. BMC Mol Biol 8:25. doi:10.1186/1471-2199-8-25. PubMed: 17376245.
11. Cheville JC, Karnes RJ, Therneau TM, Kosari F, Munz JM et al. (2008) Gene panel model predictive of outcome in men at high-risk of systemic progression and death from prostate cancer after radical retropubic prostatectomy. J Clin Oncol 26:3930-3936. doi:10.1200/JCO. 2007.15.6752. PubMed: 18711181.
12. Karnes RJ, Cheville JC, Ida CM, Sebo TJ, Nair AA et al. (2010) The ability of biomarkers to predict systemic progression in men with highrisk prostate cancer treated surgically is dependent on ERG status. Cancer Res 70:8994-9002. doi:10.1158/0008-5472. CAN-10-1358. PubMed: 21062978.
13. Stewart GD, Gray K, Pennington CJ, Edwards DR, Riddick AC et al. (2008) Analysis of hypoxia-associated gene expression in prostate cancer: lysyl oxidase and glucose transporter-1 expression correlate with Gleason score. Oncol Rep 20:1561-1567. PubMed: 19020742.
14. Yamasaki M, Nomura T, Sato F, Mimata H (2007) Metallothionein is up-regulated under hypoxia and promotes the survival of human prostate cancer cells. Oncol Rep 18:1145-1153. PubMed: 17914565.
15. Mogal AP, Watson MA, Ozsolak F, Salavaggione L, Humphrey PA (2012) Gene expression profiles and differential cytoglobin expression in atrophy and adenocarcinoma of the prostate. Prostate 72:931-937. doi:10.1002/pros.21494. PubMed: 22025306.
16. Gust KM, Hofer MD, Perner SR, Kim R, Chinnaiyan AM et al. (2009) RHAMM (CD168) is overexpressed at the protein level and may constitute an immunogenic antigen in advanced prostate cancer disease. Neoplasia 11:956-963. PubMed: 19724689.
17. Benita Y, Kikuchi H, Smith AD, Zhang MQ, Chung DC et al. (2009) An integrative genomics approach identifies Hypoxia Inducible Factor-1 (HIF-1)-target genes that form the core response to hypoxia. Nucleic Acids Res 37:4587-4602. doi:10.1093/nar/gkp425. PubMed: 19491311.
18. Lendahl U, Lee KL, Yang H, Poellinger L (2009) Generating specificity and diversity in the transcriptional response to hypoxia. Nat Rev Genet 10:821-832. doi:10.1038/nrn2722. PubMed: 19884889.
19. Ingenuity®Systems website. Available: http://www.ingenuity.com/. Accessed 2013 Nov. 10
20. Gomez LA, De Las Pozas A, Reiner T, Burnstein K, Perez-Stable C (2007) Increased expression of cyclin B1 sensitizes prostate cancer cells to apoptosis induced by chemotherapy. Mol Cancer Ther 6:1534-1543. doi:10.1158/1535-7163. MCT-06-0727. PubMed: 17513602. (Pubitemid 46954020)
21. De Resende MF, Vieira S, Chinen LT, Chiappelli F, Da Fonseca FP et al. (2013) Prognostication of prostate cancer based on TOP2A protein and gene assessment: TOP2A in prostate cancer. J Transl Med 11:36. doi:10.1186/1479-5876- 11-36. PubMed: 23398928.
22. Bismar TA, Demichelis F, Riva A, Kim R, Varambally S et al. (2006) Defining aggressive prostate cancer using a 12-gene model. Neoplasia 8:59-68. doi:10.1593/neo.05664. PubMed: 16533427.
23. Glinsky GV, Glinskii AB, Stephenson AJ, Hoffman RM, Gerald WL (2004) Gene expression profiling predicts clinical outcome of prostate cancer. J Clin Invest 113:913-923. doi:10.1172/JCI200420032. PubMed: 15067324. (Pubitemid 38544150)
24. Singh D, Febbo PG, Ross K, Jackson DG, Manola J et al. (2002) Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 1:203-209. doi:10.1016/S1535-6108 (02) 00030-2. PubMed: 12086878. (Pubitemid 41039166)
25. Cuzick J, Berney DM, Fisher G, Mesher D, Møller H et al. (2012) Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort. Br J Cancer 106:1095-1099. doi:10.1038/bjc.2012.39. PubMed: 22361632.
26. Malhotra S, Lapointe J, Salari K, Higgins JP, Ferrari M et al. (2011) A tri-marker proliferation index predicts biochemical recurrence after surgery for prostate cancer. PLOS ONE 6:e20293. doi:10.1371/journal.pone.0020293. PubMed: 21629784.
27. Giesing M, Suchy B, Driesel G, Molitor D (2010) Clinical utility of antioxidant gene expression levels in circulating cancer cell clusters for the detection of prostate cancer in patients with prostate-specific antigen levels of 4-10 ng/mL and disease prognostication after radical prostatectomy. BJU Int 105:1000-1010. doi:10.1111/j.1464-410X. 2009.08920.x. PubMed: 19818074.
28. Carnell DM, Smith RE, Daley FM, Saunders MI, Bentzen SM et al. (2006) An immunohistochemical assessment of hypoxia in prostate carcinoma using pimonidazole: implications for radioresistance. Int J Radiat Oncol Biol Phys 65:91-99. doi:10.1016/j.ijrobp. 2005.11.044. PubMed: 16563659.
29. Soria JC, Jang SJ, Khuri FR, Hassan K, Liu D et al. (2000) Overexpression of cyclin B1 in early-stage non-small cell lung cancer and its clinical implication. Cancer Res 60:4000-4004. PubMed: 10945597. (Pubitemid 30636572)
30. Hassan KA, Ang KK, El-Naggar AK, Story MD, Lee JI et al. (2002) Cyclin B1 overexpression and resistance to radiotherapy in head and neck squamous cell carcinoma. Cancer Res 62:6414-6417. PubMed: 12438226. (Pubitemid 35364097)
31. Shin JU, Lee CH, Lee KT, Lee JK, Lee KH et al. (2012) Prognostic significance of ATM and cyclin B1 in pancreatic neuroendocrine tumor. Tumour Biol 33:1645-1651. doi:10.1007/s13277-012-0420-5. PubMed: 22707287.
32. Ishigami S, Ueno S, Nishizono Y, Matsumoto M, Kurahara H et al. (2011) Prognostic impact of CD168 expression in gastric cancer. BMC Cancer 11:106. doi:10.1186/1471-2407-11-106. PubMed: 21435222.
33. Tzankov A, Strasser U, Dirnhofer S, Menter T, Arber C et al. (2011) In situ RHAMM protein expression in acute myeloid leukemia blasts suggests poor overall survival. Ann Hematol 90:901-909. doi:10.1007/s00277-011-1159-6. PubMed: 21274712.
34. Tsou AP, Yang CW, Huang CY, Yu RC, Lee YC et al. (2003) Identification of a novel cell cycle regulated gene, HURP, overexpressed in human hepatocellular carcinoma. Oncogene 22:298-307. doi:10.1038/sj.onc.1206129. PubMed: 12527899. (Pubitemid 36174187)
35. Koffa MD, Casanova CM, Santarella R, Köcher T, Wilm M et al. (2006) HURP is part of a Ran-dependent complex involved in spindle formation. Curr Biol 16:743-754. doi:10.1016/j.cub.2006.03.056. PubMed: 16631581.
36. Zhao L, Qin LX, Ye QH, Zhu XQ, Zhang H et al. (2004) KIAA0008 gene is associated with invasive phenotype of human hepatocellular carcinoma-a functional analysis. J Cancer Res Clin Oncol 130:719-727. doi:10.1007/s00432- 004-0595-2. PubMed: 15340842.
37. Stuart JE, Lusis EA, Scheck AC, Coons SW, Lal A et al. (2011) Identification of gene markers associated with aggressive meningioma by filtering across multiple sets of gene expression arrays. J Neuropathol Exp Neurol 70:1-12. doi:10.1097/NEN. 0b013e3182018f1c. PubMed: 21157382.
38. De Reyniès A, Assié G, Rickman DS, Tissier F, Groussin L et al. (2009) Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival. J Clin Oncol 27:1108-1115. doi:10.1200/JCO.2008.18.5678. PubMed: 19139432.
39. Gudmundsson KO, Thorsteinsson L, Sigurjonsson OE, Keller JR, Olafsson K et al. (2007) Gene expression analysis of hematopoietic progenitor cells identifies Dlg7 as a potential stem cell gene. Stem Cells 25:1498-1506. doi:10.1634/stemcells.2005-0479. PubMed: 17322106. (Pubitemid 47106018)
40. Loo LW, Cheng I, Tiirikainen M, Lum-Jones A, Seifried A et al. (2012) cis-Expression QTL analysis of established colorectal cancer risk variants in colon tumors and adjacent normal tissue. PLOS ONE 7:e30477. doi:10.1371/journal. pone.0030477. PubMed: 22363440.
41. Chiu AW, Huang YL, Huan SK, Wang YC, Ju JP et al. (2002) Potential molecular marker for detecting transitional cell carcinoma. Urology 60:181-185. doi:10.1016/S0090-4295 (02) 01672-2. PubMed: 12100959. (Pubitemid 34722982)
42. Murphy AJ, Hughes CA, Barrett C, Magee H, Loftus B et al. (2007) Low-level TOP2A amplification in prostate cancer is associated with HER2 duplication, androgen resistance, and decreased survival. Cancer Res 67:2893-2898. doi:10.1158/0008-5472. CAN-06-2962. PubMed: 17363613. (Pubitemid 46548980)
43. Bassal S, Nomura N, Venter D, Brand K, McKay MJ et al. (2001) Characterization of a novel human cell-cycle-regulated homologue of Drosophila dlg1. Genomics 77:5-7. doi:10.1006/geno. 2001.6570. PubMed: 11543626. (Pubitemid 32826479)
44. Wong J, Fang G (2006) HURP controls spindle dynamics to promote proper interkinetochore tension and efficient kinetochore capture. J Cell Biol 173:879-891. doi:10.1083/jcb.200511132. PubMed: 16769820.
45. Chen X, Thiaville MM, Chen L, Stoeck A, Xuan J et al. (2012) Defining NOTCH3 target genes in ovarian cancer. Cancer Res 72:2294-2303. doi:10.1158/0008-5472. CAN-11-2181. PubMed: 22396495.
46. Wang YC, Lee YH, Huang GC, Lin YH, Fan-Chiang MH et al. (2006) Enhanced transformation and chemosensitivity of NIH3T3 cells transduced with hepatoma up-regulated protein. Biochem Biophys Res Commun 340:244-249. doi:10.1016/j.bbrc.2005.12.005. PubMed: 16364248. (Pubitemid 41827672)
47. Kuo TC, Chang PY, Huang SF, Chou CK, Chao CC (2012) Knockdown of HURP inhibits the proliferation of hepacellular carcinoma cells via downregulation of gankyrin and accumulation of p53. Biochem Pharmacol 83:758-768. doi:10.1016/j.bcp. 2011.12.034. PubMed: 22230478.
48. Danza G, Di Serio C, Rosati F, Lonetto G, Sturli N et al. (2012) Notch signaling modulates hypoxia-induced neuroendocrine differentiation of human prostate cancer cells. Mol Cancer Res 10:230-238. doi: 10.1158/1541-7786. MCR-11-0296. PubMed: 22172337.
49. Wenger RH, Stiehl DP, Camenisch G (2005) Integration of oxygen signaling at the consensus HRE. Sci STKE 2005: re12.
50. Jakubicková L, Biesová Z, Pastoreková S, Kettmann R, Pastorek J (2005) Methylation of the CA9 promoter can modulate expression of the tumor-associated carbonic anhydrase IX in dense carcinoma cell lines. Int J Oncol 26:1121-1127. PubMed: 15754010.